Financial support to help you pay for your treatment

Commercially Insured?

Resources for eligible commercial, private, employer, and state health insurance marketplace patients.

  • Co-Pay Assistance: Eligible, commercially insured patients may pay as little as $0 per month for BRAFTOVI + MEKTOVI.* There are no income requirements, forms, or faxing to enroll

*Limits, terms, and conditions apply. Patients are not eligible to use this program if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Array BioPharma Inc. reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call: 1-866-277-2927 or write: BRAFTOVI + MEKTOVI Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

On Medicare or Government Insured?

Help identifying resources for eligible patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans.

  • If you need help with the cost of your medicine and may be eligible, we can refer you to Medicare Extra Help or alternate sources of funding
  • Free medicine

If support from alternate funding sources or Medicare Extra help is not available, patients may be eligible to receive BRAFTOVI + MEKTOVI for free through the Patient Assistance Program.

Uninsured?

Help identifying resources for eligible patients without any form of healthcare coverage.

  • Help finding coverage
  • Free medicine for eligible patients through the Patient Assistance Program

Eligibility required. Criteria depends on a number of factors, including the specific medicine prescribed, insurance status, and household size and income.

For more information about patient assistance options, talk to your doctor or call 1-866-277-2927.

The Tovi2 patient and caregiver text message support programs

Help getting started on BRAFTOVI + MEKTOVI

The patient text message support program* can help support you throughout treatment. And your caregiver can sign up for the caregiver program as well.

Here are some of the features of these programs you might find helpful:

Medication and refill reminders

Nutrition and activity tips

Emotional support, including inspirational and motivational quotes

Tips on taking BRAFTOVI + MEKTOVI

1.On your mobile phone, text the word Tovi2 (or Tovi2care for caregivers) to 99181.

2. When you get a message back from us, text back AGREE to confirm your participation in the support program.

3. Then answer 3 questions:

Your name so we can personalize your messages
Your ZIP code so we can set your time zone
The date you (or your loved one) started or plan to start taking BRAFTOVI + MEKTOVI

In your text message program, enter '99181' in the 'To:' field and type the word 'TOVI2' in the 'Text Message' field, and then send message to sign up for the Tovi2 text message support program.
*BRAFTOVI + MEKTOVI text message support program. By texting Tovi2 to 99181, you consent to receive autodialed marketing and other texts from Pfizer and its service providers regarding the BRAFTOVI + MEKTOVI text message support program at the phone number provided. You understand that providing this consent is not required or a condition of purchasing any products or services. Number of messages depends on your selections. Up to 8 messages per week in the first 6 weeks and up to 2 per week, thereafter, unless you request more than this. Message and data rates may apply. Complete terms can be found at https://mhm.carespeak.com/array/terms.html and Pfizer’s privacy policy at https://www.pfizer.com/privacy. Text STOP to 99181 to opt-out.

Personalized patient support

Making your support needs a priority. Together.

At Pfizer Oncology Together™, we treat your individual needs as a priority. We can connect you with a dedicated Care Champion who has social work experience and will offer resources that may help with some of your day-to-day challenges. Because when it comes to support, we’re in this together.

Care Champion Support

At Pfizer Oncology Together, our Care Champions, who have social work experience, can provide you resources that may help with some of your day-to-day challenges*:

Emotional Support

We can connect you to diagnosis-specific support groups, an independent organization that offers short-term counseling, and a free app, developed by Pfizer Oncology, to help patients connect with loved ones and ask for the support they need.

Educational Support

To help support your overall health and well-being, we’ve created resources about physical and mental health, as well as nutrition tips and healthy recipes developed in partnership with dietitians who specialize in oncology nutrition. We can also provide you with information to help you understand your prescribed BRAFTOVI and MEKTOVI.

Practical Support

If you need assistance with transportation or lodging for treatment-related appointments, we’ll connect you to independent organizations that offer these services for free to qualifying patients.

And if you’re leaving work for a period of time during treatment, or preparing to return to work, we can send you information to help make the transition easier.

*Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.

support icon
For Live, Personalized Support

Call 1-877-744-5675 (Monday–Friday 8AM–8PM ET)
VISIT
PfizerOncologyTogether.com

A free app to help manage life with cancer

LivingWith® is a free app, developed by Pfizer Oncology, for people living with cancer and those who love them. Designed to help you connect with loved ones, ask for the support you need, remember important information from doctors’ visits and stay organized, all in one place.

Learn more at ThisIsLivingWithCancer.com

Available in English and Spanish. Download LivingWith for free.

App Store is a service mark of Apple Inc., registered in the U.S. and other countries. Google Play and the Google Play logo are trademarks of Google LLC.

The free resources offered through This Is Living With Cancer™ and LivingWith® are available to anyone living with cancer and their loved ones, and are not specific to BRAFTOVI or MEKTOVI.

Advocacy groups and helpful links

As you proceed with treatment, it is important to remember that you are not alone
Here are a few of the organizations where you can find useful information and support:

Important Safety
Information and Indication

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BRAFTOVI and MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) may cause serious side effects, including:

  • Risk of new skin cancers. BRAFTOVI, when used alone or with MEKTOVI, may cause skin cancers called cutaneous squamous cell carcinoma or basal cell carcinoma. Talk to your healthcare provider about your risk for these cancers.

    Check your skin and tell your healthcare provider right away about any skin changes, including a:

    • new wart
    • skin sore or reddish bump that bleeds or does not heal
    • change in size or color of a mole

    Your healthcare provider should check your skin before and every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.

    Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment.

  • Heart problems, including heart failure. Your healthcare provider should check your heart function before and during treatment with MEKTOVI. Call your healthcare provider right away if you have any of the following signs and symptoms of a heart problem:
    • feeling like your heart is pounding or racing
    • shortness of breath
    • swelling of your ankles and feet
    • feeling light-­headed
  • Blood clots. MEKTOVI can cause blood clots in your arms or legs, which can travel to your lungs and can lead to death. Get medical help right away if you have the following symptoms:
    • chest pain
    • sudden shortness of breath or trouble breathing
    • pain in your legs with or without swelling
    • swelling in your arms and legs
    • a cool, pale arm or leg
  • Bleeding problems. BRAFTOVI, when taken with MEKTOVI, can cause serious bleeding problems, including in your stomach or brain, that can lead to death. Call your healthcare provider and get medical help right away if you have any signs of bleeding, including:
    • headaches, dizziness, or feeling weak
    • cough up blood or blood clots
    • vomit blood or your vomit looks like “coffee grounds”
    • red or black stools that look like tar
  • Eye problems. MEKTOVI can cause serious eye problems that might lead to blindness. Call your healthcare provider right away if you develop any of these symptoms of eye problems:
    • blurred vision, loss of vision, or other vision changes
    • see colored dots
    • see halos (blurred outline around objects)
    • eye pain, swelling, or redness
  • Lung or breathing problems. MEKTOVI can cause lung or breathing problems. Tell your healthcare provider if you have any new or worsening symptoms of lung or breathing problems, including:
    • shortness of breath
    • cough
  • Liver problems. Your healthcare provider should perform blood tests to check your liver function before and during treatment with MEKTOVI. Tell your healthcare provider if you have any of the following signs and symptoms of a liver problem:
    • yellowing of your skin or the white part of your eyes (jaundice)
    • dark or brown (tea­-colored) urine
    • nausea or vomiting
    • loss of appetite
  • Muscle problems (rhabdomyolysis). MEKTOVI can cause muscle problems that can be severe. MEKTOVI may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider should perform a blood test to check your CPK levels before and during treatment. Tell your healthcare provider right away if you develop any of these symptoms:
    • weakness
    • muscle aches or pain
    • dark, reddish urine
  • Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start taking BRAFTOVI with MEKTOVI and during your treatment to check your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, light-­headed, dizzy, or if you feel your heart beating irregularly or fast while taking BRAFTOVI with MEKTOVI. These symptoms may be related to QT prolongation.

Tell your healthcare team if you are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby. Females who are able to become pregnant should use effective non-hormonal birth control (contraception) during and for at least:

    • 2 weeks after the last dose of BRAFTOVI
    • 30 days after the last dose of MEKTOVI
    • Birth control methods that contain hormones (such as birth control pills, injections, or transdermal systems) may not work as well during treatment with BRAFTOVI.
    • Your healthcare team will do a pregnancy test before you start taking BRAFTOVI and MEKTOVI. Tell your healthcare provider right away if you become pregnant or think you might become pregnant during treatment.

Talk to your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment with BRAFTOVI and MEKTOVI and for:

    • 2 weeks after the final dose of BRAFTOVI
    • 3 days after the final dose of MEKTOVI

BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

The most common side effects of BRAFTOVI when taken with MEKTOVI, include: fatigue, nausea, diarrhea, vomiting, abdominal pain, and pain or swelling of your joints.

Before taking BRAFTOVI + MEKTOVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have had bleeding problems
  • have eye problems
  • have heart problems, including a condition called long QT syndrome
  • have been told that you have low blood levels of potassium, calcium, or magnesium
  • have liver or kidney problems
  • have had blood clots
  • have lung or breathing problems
  • have any muscle problems
  • have high blood pressure (hypertension)
  • are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over­-the­-counter medicines, vitamins, and herbal supplements. BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.

These are not all the possible side effects of BRAFTOVI and MEKTOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects related to BRAFTOVI + MEKTOVI products at 1-844-792-7729.

Please see both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Patient Information for additional information.

What is BRAFTOVI + MEKTOVI?

BRAFTOVI and MEKTOVI are prescription medicines used together to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • that has a certain type of abnormal “BRAF” gene

BRAFTOVI should not be used to treat people with wild­type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you.

It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.

Important Safety
Information and Indication

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BRAFTOVI and MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) may cause serious side effects, including:

  • Risk of new skin cancers. BRAFTOVI, when used alone or with MEKTOVI, may cause skin cancers called cutaneous squamous cell carcinoma or basal cell carcinoma. Talk to your healthcare provider about your risk for these cancers.

    Check your skin and tell your healthcare provider right away about any skin changes, including a:

    • new wart
    • skin sore or reddish bump that bleeds or does not heal
    • change in size or color of a mole

    Your healthcare provider should check your skin before and every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.

    Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment.

  • Heart problems, including heart failure. Your healthcare provider should check your heart function before and during treatment with MEKTOVI. Call your healthcare provider right away if you have any of the following signs and symptoms of a heart problem:
    • feeling like your heart is pounding or racing
    • shortness of breath
    • swelling of your ankles and feet
    • feeling light-­headed
  • Blood clots. MEKTOVI can cause blood clots in your arms or legs, which can travel to your lungs and can lead to death. Get medical help right away if you have the following symptoms:
    • chest pain
    • sudden shortness of breath or trouble breathing
    • pain in your legs with or without swelling
    • swelling in your arms and legs
    • a cool, pale arm or leg
  • Bleeding problems. BRAFTOVI, when taken with MEKTOVI, can cause serious bleeding problems, including in your stomach or brain, that can lead to death. Call your healthcare provider and get medical help right away if you have any signs of bleeding, including:
    • headaches, dizziness, or feeling weak
    • cough up blood or blood clots
    • vomit blood or your vomit looks like “coffee grounds”
    • red or black stools that look like tar
  • Eye problems. MEKTOVI can cause serious eye problems that might lead to blindness. Call your healthcare provider right away if you develop any of these symptoms of eye problems:
    • blurred vision, loss of vision, or other vision changes
    • see colored dots
    • see halos (blurred outline around objects)
    • eye pain, swelling, or redness
  • Lung or breathing problems. MEKTOVI can cause lung or breathing problems. Tell your healthcare provider if you have any new or worsening symptoms of lung or breathing problems, including:
    • shortness of breath
    • cough
  • Liver problems. Your healthcare provider should perform blood tests to check your liver function before and during treatment with MEKTOVI. Tell your healthcare provider if you have any of the following signs and symptoms of a liver problem:
    • yellowing of your skin or the white part of your eyes (jaundice)
    • dark or brown (tea­-colored) urine
    • nausea or vomiting
    • loss of appetite
  • Muscle problems (rhabdomyolysis). MEKTOVI can cause muscle problems that can be severe. MEKTOVI may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider should perform a blood test to check your CPK levels before and during treatment. Tell your healthcare provider right away if you develop any of these symptoms:
    • weakness
    • muscle aches or pain
    • dark, reddish urine
  • Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start taking BRAFTOVI with MEKTOVI and during your treatment to check your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, light-­headed, dizzy, or if you feel your heart beating irregularly or fast while taking BRAFTOVI with MEKTOVI. These symptoms may be related to QT prolongation.

Tell your healthcare team if you are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby. Females who are able to become pregnant should use effective non-hormonal birth control (contraception) during and for at least:

    • 2 weeks after the last dose of BRAFTOVI
    • 30 days after the last dose of MEKTOVI
    • Birth control methods that contain hormones (such as birth control pills, injections, or transdermal systems) may not work as well during treatment with BRAFTOVI.
    • Your healthcare team will do a pregnancy test before you start taking BRAFTOVI and MEKTOVI. Tell your healthcare provider right away if you become pregnant or think you might become pregnant during treatment.

Talk to your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment with BRAFTOVI and MEKTOVI and for:

    • 2 weeks after the final dose of BRAFTOVI
    • 3 days after the final dose of MEKTOVI

BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

The most common side effects of BRAFTOVI when taken with MEKTOVI, include: fatigue, nausea, diarrhea, vomiting, abdominal pain, and pain or swelling of your joints.

Before taking BRAFTOVI + MEKTOVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have had bleeding problems
  • have eye problems
  • have heart problems, including a condition called long QT syndrome
  • have been told that you have low blood levels of potassium, calcium, or magnesium
  • have liver or kidney problems
  • have had blood clots
  • have lung or breathing problems
  • have any muscle problems
  • have high blood pressure (hypertension)
  • are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over­-the­-counter medicines, vitamins, and herbal supplements. BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.

These are not all the possible side effects of BRAFTOVI and MEKTOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects related to BRAFTOVI + MEKTOVI products at 1-844-792-7729.

Please see both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Patient Information for additional information.

What is BRAFTOVI + MEKTOVI?

BRAFTOVI and MEKTOVI are prescription medicines used together to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • that has a certain type of abnormal “BRAF” gene

BRAFTOVI should not be used to treat people with wild­type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you.

It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.